Showing results (1121-1130 of 4,514) with videos related to

Sort By:
Pageof 452
Future Oncology (London, England)|July 29, 2026
Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancerArun A Azad, Bhavik J Pandya, Hemant Singh Bhadauria, et al.
Future Oncology (London, England)|August 4, 2026
Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene studyShan Xu, Hao Yang, Nan Hu
Future Oncology (London, England)|July 31, 2026
Treatment patterns in relapsed/refractory marginal zone lymphoma: real-world evidence from seven countriesHarshali Patel, Lynn Huynh, Patrick Squires, et al.
Future Oncology (London, England)|April 13, 2019
AIPAC: a Phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancerLuc Dirix, Frédéric Triebel
Future Oncology (London, England)|June 30, 2026
VEBrant: a multicenter, phase II study of MET inhibitor vebreltinib combined with PD-1-based immunotherapy in advanced clear cell sarcomaYaling Jiang, Nong Lin, Xin Huang, et al.
Future Oncology (London, England)|July 1, 2026
Disparities in mortality among HER2-positive breast cancer patients treated with trastuzumab in Chile (2015-2024): real-world evidence from 4,920 casesYanara A Bernal, Allison Landeros-Contreras, Edgardo Rojas-Mancilla, et al.
Future Oncology (London, England)|November 17, 2020
Estimate of multiple myeloma patients by line of therapy in the USA: population-level projections 2020-2025Gena Kanas, Otavio Clark, Katie Keeven, et al.
Future Oncology (London, England)|July 11, 2015
Nanotechnology in the war against cancer: new arms against an old enemy - a clinical viewSten Friberg, Andreas M Nyström
Future Oncology (London, England)|July 9, 2026
Synthetic lethality targets in pancreatic ductal adenocarcinoma: prevalence and limitations of liquid biopsy detection in a minority-serving cancer centerMahmoud Abdelsamia, Yafang Li, Daniel Eastwood, et al.
Future Oncology (London, England)|April 6, 2026
Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II studyEziafa I Oduah, Tian Zhang, Sin-Ho Jung, et al.
Pageof 452